15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $13M | -$124M | 49.3% | -959.1% | -$103M | — | $208M |
| 2024 | $10M | -$130M | 23.1% | -1354.3% | -$61M | $9M | $99M |
| 2023 | $8M | -$117M | 39.0% | -1523.9% | -$110M | $11M | $25M |
| 2022 | — | -$110M | — | — | -$146M | — | $120M |
| 2021 | — | -$92M | — | — | -$111M | — | $179M |
| 2020 | — | -$50M | — | — | -$57M | — | $77M |
| 2019 | — | -$29M | — | — | -$27M | — | $11M |
| 2018 | — | -$26M | — | — | -$24M | — | $25M |
| 2017 | — | -$21M | — | — | -$19M | — | $25M |
| 2016 | — | -$39M | — | — | -$37M | — | $19M |
| 2015 | — | -$48M | — | — | — | — | $19M |
| 2014 | — | -$28M | — | — | — | — | $38M |
| 2014 | — | -$32M | — | — | — | — | — |
| 2013 | — | -$11M | — | — | — | — | $8M |
| 2013 | — | -$23M | — | — | -$15M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $7M | -$40M | 77.1% | -603.9% | -$44M | — | $185M |
| Dec '25 | $5M | -$47M | 80.4% | -895.8% | -$42M | — | $208M |
| Sep '25 | $3M | -$32M | 58.4% | -1005.1% | -$30M | — | $190M |
| Jun '25 | $2M | -$28M | -63.8% | -1416.2% | -$15M | — | $125M |
| Mar '25 | $2M | -$17M | 61.2% | -660.9% | -$17M | — | $132M |
| Dec '24 | $3M | -$22M | 54.2% | -870.6% | -$15M | $9M | $99M |
| Sep '24 | $3M | -$14M | 44.9% | -551.2% | -$19M | $9M | $28M |
| Jun '24 | $2M | -$79M | -52.5% | -3501.6% | -$10M | $10M | $4M |
| Mar '24 | $2M | -$15M | 33.1% | -860.2% | -$18M | $11M | $7M |
| Dec '23 | $4M | -$27M | 37.4% | -723.2% | -$23M | $11M | $25M |
| Sep '23 | $4M | -$28M | 40.5% | -705.6% | -$25M | — | $7M |
| Jun '23 | — | -$28M | — | — | -$25M | — | $26M |
| Mar '23 | — | -$33M | — | — | -$37M | — | $72M |
| Dec '22 | — | -$32M | — | — | -$27M | — | $120M |
| Sep '22 | — | -$29M | — | — | -$32M | — | $140M |
| Jun '22 | — | -$23M | — | — | -$36M | — | $145M |
| Mar '22 | — | -$26M | — | — | -$51M | — | $140M |
| Dec '21 | — | -$30M | — | — | -$48M | — | $179M |
| Sep '21 | — | -$19M | — | — | -$21M | — | $183M |
| Jun '21 | — | -$24M | — | — | -$21M | — | $166M |
How the market has priced TNXP against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Tonix Pharmaceuticals Holding Corp.'s revenue has grown 29.9% per year. These are computed facts, not advice.
As of FY2025, Tonix Pharmaceuticals Holding Corp. reported — of total debt against $208M of cash; operating income covered interest expense -1412.4×.
In FY2025, gross margin was 49.3%, operating margin -959.1%, and net margin -946.2%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.